Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05038488 · ClinicalTrials.gov registry record · Phase 2
Phase 2a MIB-626 vs. Placebo COVID-19
A Phase 2 study, sponsored by Metro International Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT05038488 is a Phase 2 study that has completed, run by Metro International Biotech. The registered enrollment target is 42 participants.
The verdict
NCT05038488, a Phase 2 study, has completed, sponsored by Metro International Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by longitudinal changes in serum creatinine concentration, and in attenuating the inflammatory response to the infection.
Interventions
- DRUG Placebo
- DRUG MIB-626
- OTHER Home Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-10-26 |
| Est. Completion | 2023-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05038488
The ClinicalTrials.gov registry entry for NCT05038488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Metro International Biotech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05038488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05038488 about?
NCT05038488 is a clinical study titled "Phase 2a MIB-626 vs. Placebo COVID-19". The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by longitudinal changes in serum creatinine concentration, and in attenuatin...
What is the current status of trial NCT05038488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2021-10-26. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT05038488?
The interventions under investigation include: Placebo (DRUG), MIB-626 (DRUG), Home Treatment (OTHER).
Who is sponsoring clinical trial NCT05038488?
This trial is sponsored by Metro International Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.